Literature DB >> 19087417

Endogenous cannabinoids and appetite.

T C Kirkham1, C M Williams.   

Abstract

Since pre-history, Cannabis sativa has been exploited for its potent and manifold pharmacological actions. Amongst the most renowned of these actions is a tendency to provoke ravenous eating. The characterization of the psychoactive principals in cannabis (exogenous cannabinoids) and, more recently, the discovery of specific brain cannabinoid receptors and their endogenous ligands (endocannabinoids) has stimulated research into the physiological roles of endocannabinoid systems. In this review, we critically discuss evidence from the literature that describe studies on animals and human subjects to support endocannabinoid involvement in the control of appetite. We describe the hyperphagic actions of the exogenous cannabinoid, Delta9-tetrahydrocannabinol, and the endogenous CB1 ligands, anandamide and 2-arachidonylglycerol, and present evidence to support a specific role of endocannabinoid systems in appetitive processes related to the incentive and reward properties of food. A case is made for more comprehensive and systematic analyses of cannabinoid actions on eating, in the anticipation of improved therapies for disorders of appetite and body weight, and a better understanding of the biopsychological processes underlying hunger.

Entities:  

Year:  2001        PMID: 19087417     DOI: 10.1079/NRR200118

Source DB:  PubMed          Journal:  Nutr Res Rev        ISSN: 0954-4224            Impact factor:   7.800


  35 in total

1.  The cannabinoid receptor antagonist SR 141716 attenuates overfeeding induced by systemic or intracranial morphine.

Authors:  Aaron N A Verty; Malini E Singh; Iain S McGregor; Paul E Mallet
Journal:  Psychopharmacology (Berl)       Date:  2003-04-17       Impact factor: 4.530

Review 2.  Antagonizing the cannabinoid receptor type 1: a dual way to fight obesity.

Authors:  D Cota; S Genghini; R Pasquali; U Pagotto
Journal:  J Endocrinol Invest       Date:  2003-10       Impact factor: 4.256

3.  The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin.

Authors:  Sonia A Tucci; Elizabeth K Rogers; Marta Korbonits; Tim C Kirkham
Journal:  Br J Pharmacol       Date:  2004-09-20       Impact factor: 8.739

4.  Noladin ether, a putative endocannabinoid, enhances motivation to eat after acute systemic administration in rats.

Authors:  E K Jones; T C Kirkham
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

5.  The cannabinoid CB1 receptor antagonist SR141716A reduces appetitive and consummatory responses for food.

Authors:  Zoë D Thornton-Jones; Steven P Vickers; Peter G Clifton
Journal:  Psychopharmacology (Berl)       Date:  2004-11-18       Impact factor: 4.530

Review 6.  'Liking' and 'wanting' food rewards: brain substrates and roles in eating disorders.

Authors:  Kent C Berridge
Journal:  Physiol Behav       Date:  2009-03-29

7.  Cannabis constituents modulate δ9-tetrahydrocannabinol-induced hyperphagia in rats.

Authors:  Jonathan A Farrimond; Andrew J Hill; Benjamin J Whalley; Claire M Williams
Journal:  Psychopharmacology (Berl)       Date:  2010-03-27       Impact factor: 4.530

8.  The neutral cannabinoid CB₁ receptor antagonist AM4113 regulates body weight through changes in energy intake in the rat.

Authors:  Nina L Cluny; Adam P Chambers; V Kiran Vemuri; Jodianne T Wood; Lindsay K Eller; Carmelina Freni; Raylene A Reimer; Alexandros Makriyannis; Keith A Sharkey
Journal:  Pharmacol Biochem Behav       Date:  2010-11-04       Impact factor: 3.533

9.  The multiple functions of the endocannabinoid system: a focus on the regulation of food intake.

Authors:  Eduardo Tibiriça
Journal:  Diabetol Metab Syndr       Date:  2010-01-21       Impact factor: 3.320

10.  Cannabinoids suppress synaptic input to neurones of the rat dorsal motor nucleus of the vagus nerve.

Authors:  Andrei V Derbenev; Thomas C Stuart; Bret N Smith
Journal:  J Physiol       Date:  2004-07-22       Impact factor: 5.182

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.